GoodRx (NASDAQ:GDRX) Hits New 1-Year Low – Should You Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $2.40 and last traded at $2.3750, with a volume of 543404 shares traded. The stock had previously closed at $2.52.

Analysts Set New Price Targets

Several research firms have recently weighed in on GDRX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GoodRx in a research note on Tuesday, December 23rd. Mizuho decreased their price objective on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Citigroup decreased their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Jefferies Financial Group downgraded shares of GoodRx to a “hold” rating in a research note on Thursday, January 22nd. Finally, UBS Group restated a “reduce” rating on shares of GoodRx in a research note on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.73.

GoodRx Stock Performance

The firm has a market cap of $799.36 million, a price-to-earnings ratio of 26.28, a PEG ratio of 0.97 and a beta of 1.45. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The company has a 50 day moving average of $2.74 and a 200 day moving average of $3.64.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same period in the previous year, the company earned $0.08 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. As a group, equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after buying an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after acquiring an additional 184,734 shares during the period. LSV Asset Management grew its position in shares of GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after acquiring an additional 1,973,017 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of GoodRx by 16.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock worth $8,324,000 after acquiring an additional 236,896 shares during the period. Finally, Pathway Capital Management LP lifted its position in GoodRx by 69.0% in the 3rd quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock valued at $4,171,000 after purchasing an additional 402,721 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.